Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT02574455
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free survival (PFS) in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) previously treated with at least two systemic chemotherapy regimens for unresectable, locally advanced or metastatic disease, and without brain metastasis at baseline.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 529
- Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. Triple negative is defined as <1% expression for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) by in-situ hybridization.
- Refractory to or relapsed after at least two prior standard therapeutic regimens for advanced/metastatic TNBC.
- Prior exposure to a taxane in localized or advanced/metastatic setting.
- Eligible for one of the chemotherapy options listed as TPC (eribulin, capecitabine, gemcitabine, or vinorelbine) as per investigator assessment.
- Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
- Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Bone-only disease is not permitted.
- At least 2 weeks beyond prior anti-cancer treatment (chemotherapy, endocrine therapy, radiotherapy, and/or major surgery), and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).
- At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).
- Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL, absolute neutrophil count (ANC) > 1,500 per mm^3, platelets > 100,000 per mm^3).
- Adequate renal and hepatic function (creatinine clearance [CrCL] > 60 mL/min, bilirubin ≤ 1.5 institutional upper limit of normal [IULN], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin ≥3 g/dL).
- Recovered from all toxicities to Grade 1 or less by National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) v4.03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Participants with Grade 2 neuropathy are eligible but may not receive vinorelbine as TPC.
- Participants with treated, non-progressive brain metastases, off high-dose steroids (>20 mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.
Key
- Women who are pregnant or lactating.
- Women of childbearing potential or fertile men unwilling to use effective contraception during study and up to three months after treatment discontinuation in women of child-bearing potential and six months in males post last study drug.
- Participants with Gilbert's disease.
- Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while participants with other prior malignancies must have had at least a 3-year disease-free interval.
- Participants known to be human immunodeficiency (HIV) positive, hepatitis B positive, or hepatitis C positive.
- Infection requiring antibiotic use within one week of randomization.
- Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment of Physician's Choice (TPC) Eribulin Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs. Treatment of Physician's Choice (TPC) Capecitabine Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs. Sacituzumab Govitecan Sacituzumab govitecan Participants will receive sacituzumab govitecan on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable adverse events (AEs). Treatment of Physician's Choice (TPC) Gemcitabine Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs. Treatment of Physician's Choice (TPC) Vinorelbine Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) PFS was defined as the time from randomization until objective tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (greater than or equal to \[≥\] 20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) by IRC and Investigator Assessment in BM-ve Population From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) ORR was defined as the percentage of participants who had the overall best response as either a confirmed complete response (CR) or partial response (PR) relative to the size of population under evaluation. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and no new lesions.
Duration of Response (DOR) by IRC and Investigator Assessment in BM-ve Population From the first date of documented response of CR or PR to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) DOR was defined as the number of days between the first date showing a documented response of CR or PR and the date of progression or death. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions.
Overall Survival (OS) in BM-ve Population From the randomization to death from any cause (maximum follow-up duration: 30.8 months) Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.
Time to Objective Response by the IRC Assessment in BM-ve Population From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.
Progression-Free Survival (PFS) by IRC Assessment in the ITT Population From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) PFS was defined as the time from randomization until objective tumor progression by RECIST v1.1 or death, whichever came first. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. PFS was estimated using Kaplan-Meier estimate.
Overall Survival (OS) in ITT Population From the randomization to death from any cause (maximum follow-up duration: 30.8 months) Overall survival (OS) was defined as the time from the randomization to death from any cause. OS was estimated using Kaplan-Meier estimate.
Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation of Study Drug First dose date up to last follow-up (maximum up to 30.8 months) Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious:
* Fatal
* Life-threatening
* Disabling/incapacitating
* Results in hospitalization or prolongs a hospital stay
* A congenital abnormality
* Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed aboveChange From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score Baseline; End of Treatment (EOT) (up to 29.6 months) The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.
Time to Progression (TTP) by Investigator Assessment in BM-ve Population From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.
Time to Objective Response by the Investigator Assessment in BM-ve Population From randomization to the first recorded objective response (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) Time to response was defined as the time from randomization to the first recorded objective response (ie, CR or PR). CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions.
Time to Progression (TTP) by IRC Assessment in BM-ve Population From randomization until disease progression (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) Time to Progression (TTP) was defined as the time from the date of randomization to the date of the first evidence of disease progression as assessed using RECIST 1.1 criteria. The date of progression was date of the last observation or radiological assessment of target lesions that either showed a predefined increase (≥20%) in the sum of the target lesions or the appearance of new non-target lesions. Participants without progression were censored.
Percentage of Participants Experiencing the Worst Laboratory Abnormalities Grade 3 or 4 Post-Baseline First dose date up to last follow-up (maximum up to 30.8 months) Blood samples were collected for hematology, serum chemistry and the laboratory abnormalities were assessed. The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 are reported.
Clinical Benefit Rate (CBR) by IRC and Investigator Assessment in BM-ve Population From randomization to the date of progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months) CBR was defined as the percentage of participants with best response as either CR, PR, or stable disease (SD) with a duration of ≥6 months. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; and no new lesions. PR: ≥30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started; and Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits. PD: ≥20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since treatment started or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Trial Locations
- Locations (178)
Southern Cancer Center, 29653 Anchor Cross Blvd
🇺🇸Daphne, Alabama, United States
Souther Cancer Center, 3719 Dauphin St., 5 Floor
🇺🇸Mobile, Alabama, United States
Southern Cancer Center, 3 Mobile Infirmary Circle
🇺🇸Mobile, Alabama, United States
UCLA Jonsson Comprehensive Cancer Center, 1411 S. Garfield Ave Suite 200
🇺🇸Alhambra, California, United States
UCLA Jonsson Comprehensive Cancer Center, 201. S. Buena Vista St Suite 200
🇺🇸Burbank, California, United States
UCLA Jonsson Comprehensive Cancer Center
🇺🇸Laguna Hills, California, United States
UCLA Jonsson Comprehensive Cancer Center, 625 South Fair Oaks Avenue Suite 320
🇺🇸Pasadena, California, United States
UCLA Jonsson Comprehensive Cancer Center, 200 UCLA Medical Plaza
🇺🇸Los Angeles, California, United States
UCLA Jonsson Comprehensive Cancer Center, 2020 Santa Monica Boulevard
🇺🇸Santa Monica, California, United States
Northside Hospital
🇺🇸Atlanta, Georgia, United States
University of Colorado Hospital - Anschutz Cancer Pavilion, 1665 Aurora Court
🇺🇸Aurora, Colorado, United States
Rocky Mountain Cancer Centers, 4715 Arapahoe Ave
🇺🇸Boulder, Colorado, United States
Rocky Mountain Cancer Centers, 2312 N. Nevada Avenue, Suite 400
🇺🇸Colorado Springs, Colorado, United States
Rocky Mountain Cancer Centers, 499 E Hampden Ave Suite 450
🇺🇸Englewood, Colorado, United States
Rocky Mountain Cancer Centers, 11750 West 2nd Place, Suite 1-100
🇺🇸Lakewood, Colorado, United States
Rocky Mountain Cancer Centers, 22 West Dry Creek Circle
🇺🇸Littleton, Colorado, United States
Rocky Mountain Cancer Centers, 10103 Ridge Gate Parkway, Suite G-01
🇺🇸Lone Tree, Colorado, United States
Rocky Mountain Cancer Centers, 9397 Crown Crest Blvd., Suite 421
🇺🇸Parker, Colorado, United States
Rocky Mountain Cancer Centers, 3676 Parker Blvd., Suite 350
🇺🇸Pueblo, Colorado, United States
Rocky Mountain Cancer Centers, 8820 Huron Street
🇺🇸Thornton, Colorado, United States
Yale School Of Medicine
🇺🇸New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute, 601 E. Altamonte Drive
🇺🇸Altamonte Springs, Florida, United States
Florida Cancer Specialist
🇺🇸Bonita Springs, Florida, United States
Florida Cancer Specialists
🇺🇸Venice, Florida, United States
Florida Cancer Specialists & Research Institute, 403 S. King Ave
🇺🇸Brandon, Florida, United States
Florida Cancer Specialists & Research Institute, 3280 McMullen Booth road
🇺🇸Clearwater, Florida, United States
Sylvester Comprehensive Cancer Center
🇺🇸Plantation, Florida, United States
Florida Cancer Specialists & Research Institute, 224 Memorial medical Parway
🇺🇸Daytona Beach, Florida, United States
Florida Cancer Specialists & Research Institute, 6420 W Newberry Road Est Wing
🇺🇸Gainesville, Florida, United States
Florida Cancer Specialists & Research Institute, 100 Highland Avenue
🇺🇸Largo, Florida, United States
Florida Cancer Specialists & Research Institute, 521 N. Lecanto Highway
🇺🇸Lecanto, Florida, United States
Florida Cancer Specialists & Research Institute, 8763 River Crossing Blvd
🇺🇸New Port Richey, Florida, United States
Florida Cancer Specialists & Research Institute, 1630 SE 18th ST
🇺🇸Ocala, Florida, United States
Florida Cancer Specialists & Research Institute, 765 Image Way
🇺🇸Orange City, Florida, United States
Florida Cancer Specialists & Research Institute - 325 Clyde Morris
🇺🇸Ormond Beach, Florida, United States
Orlando Regional Medical Center
🇺🇸Orlando, Florida, United States
Florida Cancer Specialists & Research Institute, 70 W Gore Street
🇺🇸Orlando, Florida, United States
Florida Cancer Specialists & Research Institute, 560 Jackson St
🇺🇸Saint Petersburg, Florida, United States
Florida Cancer Specialists & Research Institute, 1201 Fifth Avenue North
🇺🇸Saint Petersburg, Florida, United States
Florida Cancer Specialists & Research Institute, 7154 Medical Center Drive
🇺🇸Spring Hill, Florida, United States
Florida Cancer Specialists & Research Institute, 3402 W Dr. Martin Luther King Jr Boulevard
🇺🇸Tampa, Florida, United States
Florida Cancer Specialists & Research Institute, 1400 US highway 441 N
🇺🇸The Villages, Florida, United States
Florida Cancer Specialists & Research Institute, 4100 Waterman Way
🇺🇸Tavares, Florida, United States
Florida Cancer Specialists & Research Institute1309 N Flagler Dr
🇺🇸West Palm Beach, Florida, United States
Florida Cancer Specialists & Research Institute - 3730 7th Terrace
🇺🇸Vero Beach, Florida, United States
Florida Cancer Specialists & Research Institute, 2100 Glenwood Drive
🇺🇸Winter Park, Florida, United States
University Cancer & Blood Center, 3320 Old Jefferson Rd
🇺🇸Athens, Georgia, United States
Atlanta Cancer Care - Atlanta
🇺🇸Atlanta, Georgia, United States
GCS/Annex
🇺🇸Atlanta, Georgia, United States
GCS/Canton
🇺🇸Canton, Georgia, United States
Atlanta Cancer Care - Conyers
🇺🇸Conyers, Georgia, United States
Atlanta Cancer Care - Cumming
🇺🇸Cumming, Georgia, United States
Atlanta Cancer Care - Decatur
🇺🇸Decatur, Georgia, United States
GCS/Stemmer
🇺🇸Decatur, Georgia, United States
Atlanta Cancer Care - Stockbridge
🇺🇸Jonesboro, Georgia, United States
GCS/Macon
🇺🇸Macon, Georgia, United States
GCS/Kennestone
🇺🇸Marietta, Georgia, United States
GCS/Northside
🇺🇸Sandy Springs, Georgia, United States
Illinois Cancer Specialists
🇺🇸Niles, Illinois, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital 1900 Silver Cross Blvd
🇺🇸New Lenox, Illinois, United States
MidAmerica Division Inc. c/o Menorah Medical Center
🇺🇸Independence, Missouri, United States
Orland Park - UCMC Center for Advanced Care 14290 South LaGrange Rd
🇺🇸Orland Park, Illinois, United States
Mass General - North Shore Cancer Center ( NSCC )
🇺🇸Danvers, Massachusetts, United States
Mercy Hospital
🇺🇸Coon Rapids, Minnesota, United States
Suburban Imaging Northwest
🇺🇸Coon Rapids, Minnesota, United States
Suburban Imaging
🇺🇸Coon Rapids, Minnesota, United States
Mercy Hospital - Unity Campus AHL
🇺🇸Fridley, Minnesota, United States
Washington University School of Medicine in St. Louis
🇺🇸Saint Louis, Missouri, United States
Research Medical Center
🇺🇸Kansas City, Missouri, United States
New York Oncology Hematology, P.C.
🇺🇸Clifton Park, New York, United States
North Shore Hematology Oncology Associates., PC, 235 North Belle Mead Road
🇺🇸East Setauket, New York, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
North Shore Hematology Oncology Associates., PC, 285 Sills Road Building 16
🇺🇸Patchogue, New York, United States
UNC Health Care System
🇺🇸Chapel Hill, North Carolina, United States
UPMC Hillman Cancer Center Mountainview Arnold Palmer Pavilion
🇺🇸Greensburg, Pennsylvania, United States
UPMC Hillman Cancer Center UPMC East
🇺🇸Monroeville, Pennsylvania, United States
Tennessee Oncology - Chattanooga Oncology & Hematology Associates
🇺🇸Chattanooga, Tennessee, United States
West Cancer Center, 7945 Wolf River Blvd
🇺🇸Germantown, Tennessee, United States
Tennessee Oncology, LLC
🇺🇸Shelbyville, Tennessee, United States
Center for Cancer and Blood Disorders
🇺🇸Weatherford, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Texas Oncology
🇺🇸Plano, Texas, United States
Texas Oncology-Longview Cancer Center
🇺🇸Longview, Texas, United States
Virginia Cancer Specialists, PC
🇺🇸Woodbridge, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
🇺🇸Wytheville, Virginia, United States
Virginia Oncology Associates, P.C.
🇺🇸Norfolk, Virginia, United States
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
🇺🇸Salem, Virginia, United States
Universitair Zlekenhuis Brussel
🇧🇪Brussels, Belgium
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
Maryland Oncology Hematology
🇺🇸Silver Spring, Maryland, United States
Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Paul Papin
🇫🇷Angers, France
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besançon, France
Institut Régional du Cancer de Montpellier
🇫🇷Montpellier, France
Institut Curie
🇫🇷Paris, France
Centre Eugène Marquis
🇫🇷Rennes Cedex, France
Florence Lerebours
🇫🇷Saint-Cloud, France
CHU de Nantes - Hôpital Nord Laennec
🇫🇷Saint-Herblain, France
Institut Claudius Regaud
🇫🇷Toulouse, France
Gustave Roussy
🇫🇷Villejuif, France
Rocky Mountain Cancer Centers, 2030 W Mountain View Avenue, Ste. 210
🇺🇸Longmont, Colorado, United States
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus
🇩🇪Frankfurt, Germany
Texas Oncology- Medical City Dallas Building D
🇺🇸Dallas, Texas, United States
Virginia Oncology Associates
🇺🇸Virginia Beach, Virginia, United States
Praxis für interdisziplinäre Onkologie & Hämatologie GbR
🇩🇪Freiburg im Breisgau, Germany
Facharztzentrum Eppendorf
🇩🇪Hamburg, Germany
Praxis für Hämatologie und Internistische Onkologie
🇩🇪Velbert, Germany
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Teresa Herrera, As Xubias, 84
🇪🇸A Coruña, Spain
Hospital Quirón Barcelona, Plaza Alfonso Comín 5
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau, Carrer del Mas Casanovas, 90
🇪🇸Barcelona, Spain
Institut Catala d'Oncologia Hospitalet, Avenida Gran Via 199-203
🇪🇸Hospitalet de Llobregat, Spain
Hospital Universitari Arnau de Vilanova de Lleida
🇪🇸Lleida, Spain
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinco Universaitario
🇪🇸Santiago De Compostela, Spain
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Colchester Hospital University NHS Foundation Trust - Colchester General Hospital, Turner Road
🇬🇧Colchester, ESS, United Kingdom
The Arden Cancer Centre- University Hospital Coventry
🇬🇧Coventry, United Kingdom
County Durham and Darlington NHS Foundation Trust - University Hospital of North Durham
🇬🇧Durham, United Kingdom
The Royal Surrey County Hospital NHS Foundation Trust
🇬🇧Guildford, United Kingdom
The County Hospital, Wye Valley NHS Trust
🇬🇧Hereford, United Kingdom
The Royal Free London NHS Foundation Trust - The Royal Free Hospital, Pond Street Oncology & Haematology Clinical Trials Unit Dept. of Academic Oncology
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Nottingham University Hospitals NHS Trust - City Hospital
🇬🇧Nottingham, United Kingdom
Plymouth Hospitals NHS Trust - Derriford Hospital
🇬🇧Plymouth, United Kingdom
Taunton and Somerset NHS Foundation Trust - Musgrove Park Hospital, Musgrove Park Hospital
🇬🇧Taunton, United Kingdom
The Mid Yorkshire Hospitals NHS Trust - Pinderfields Hospital
🇬🇧Wakefield, United Kingdom
University of Chicago Medical Center 5841 S. Maryland Ave
🇺🇸Chicago, Illinois, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center (BIDMC)
🇺🇸Boston, Massachusetts, United States
The Ohio State University Wexner Medical Center, 460 W 10th Ave
🇺🇸Columbus, Ohio, United States
The Ohio State University Wexner Medical Center, 1145 Olentangy River Road
🇺🇸Columbus, Ohio, United States
UPMC Hillman Cancer Center Upper Saint Clair
🇺🇸Pittsburgh, Pennsylvania, United States
Magee-Womens Hospital of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Allegheny-Singer Research Institute, 320 East North Avenue
🇺🇸Pittsburgh, Pennsylvania, United States
UPMC Hillman Cancer Center UPMC Passavant
🇺🇸Pittsburgh, Pennsylvania, United States
Houston Methodist Hospital - 6565 Fannin St
🇺🇸Houston, Texas, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Baptist Health Medical Group Oncology, LLC
🇺🇸Miami, Florida, United States
Virginia G. Piper Cancer Center at HonorHealth
🇺🇸Minneapolis, Minnesota, United States
Minnesota Oncology Hematology P.A.
🇺🇸Minneapolis, Minnesota, United States
Abbot Northwestern Hospital
🇺🇸Minneapolis, Minnesota, United States
University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, 1600 Divisadero Street
🇺🇸San Francisco, California, United States
Tennessee Ocology, LLC
🇺🇸Nashville, Tennessee, United States
Vanderbilt Breast Cancer Center at One Hundred Oaks 719 Thompson Lane, Suite 25000
🇺🇸Nashville, Tennessee, United States
Henry-Joyce Cancer Clinic 1301 Medical Center Drive 1903 The Vanderbilt Clinic Nashville, TN 37232
🇺🇸Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion
🇺🇸Westwood, Kansas, United States
Sarah Cannon Cancer Institute/Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
Tennesee Oncology - PLLC
🇺🇸Chattanooga, Tennessee, United States
Mayo Clinic Hospital
🇺🇸Scottsdale, Arizona, United States
Jewish General Hospital, 3755 Côte-Sainte-Catherine
🇨🇦Québec, Quebec, Canada
Norwalk Hospital, 34 Maple Street
🇺🇸Norwalk, Connecticut, United States
Georgetown Lombardi Comprehensive Cancer Center
🇺🇸Washington, District of Columbia, United States
Clinique et Maternite Sainte-Elisabeth
🇧🇪Namur, Belgium
Cross Cancer Institute, 11560 University Avenue
🇨🇦Edmonton, Alberta, Canada
Tenessee Oncology
🇺🇸Nashville, Tennessee, United States
UZ Leuven
🇧🇪Leuven, Belgium
Nebraska Cancer Specialists- Midwest Cancer Center- Papillion
🇺🇸Papillion, Nebraska, United States
Tenesse Oncology - PLLC
🇺🇸Cleveland, Tennessee, United States
Rocky Mountain Cancer Centers, 4700 E. Hale Parkway, Suite 400
🇺🇸Denver, Colorado, United States
Rocky Mountain Cancer Centers, 1800 Williams St.
🇺🇸Denver, Colorado, United States
Providence Medical Group
🇺🇸Portland, Oregon, United States
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Nebraska Cancer Specialists - Midwest Cancer Center - Papillion
🇺🇸Omaha, Nebraska, United States
Mayo Clinic - 200 First Street SW
🇺🇸Rochester, Minnesota, United States
Nebraska Cancer Specialists - Midwest Cancer Center - Paillion
🇺🇸Omaha, Nebraska, United States
Southern Cancer Center, 6701 Airport Blvd., Bldg B, Terace Level
🇺🇸Mobile, Alabama, United States
Atlanta Cancer Center - Alpharetta
🇺🇸Alpharetta, Georgia, United States
Institut für Versorgungsforschung in der Onkologie
🇩🇪Koblenz, Germany
Hospital del Mar
🇪🇸Barcelona, Spain
Florida Cancer Specialists & Research Institute, 1037 State Road 7 Bldg B
🇺🇸Wellington, Florida, United States
Rocky Mountain Cancer Centers, 1700 South Potomac Street
🇺🇸Aurora, Colorado, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
US Oncology
🇺🇸Tyler, Texas, United States
Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada